Logo Prima Biomed

Welcome to the Newsroom

27 October 2015

Prima BioMed gains Belgian Regulatory Approval to commence a Registration Phase IIB Study of IMP321


- Belgium’s Federal Agency for Medicines and Health Products approved the commencement of the AIPAC study
- IMP321 Phase IIb trial initiation is expected before the end of 2015

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce its first regulatory approval facilitating commencement of the landmark Phase IIb clinical study of IMP321, Prima’s lead compound.